Takeda and Protagonist Therapeutics secured global co-development rights and received FDA approval for a drug treating rare blood cancer.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Takeda and Protagonist Therapeutics secured global co-development rights and received FDA approval for a drug treating rare blood cancer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Takeda
company in Rome, Italy
Nothing else this week.